Jeffrey D. Wayne
Expertise in
27
conditions

Dr. Jeffrey D. Wayne

Surgical Oncology | General Surgery
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
34 Years of Experience
Expertise in
27
conditions
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 

Overview

Jeffrey Wayne is a Surgical Oncologist and a General Surgeon in Chicago, Illinois. Dr. Wayne has been practicing medicine for over 34 years is highly rated in 27 conditions, according to our data. His top areas of expertise are Melanoma, Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Lymphadenectomy, and Gastrectomy.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Boston University School Of Medicine, 1992.0

Residency

University of Chicago

Specialties

Surgical Oncology
General Surgery

Licenses

Surgery in IL

Board Certifications

American Board Of Surgery - Surgery (Certified)

Fellowships

University of Texas M D Anderson Cancer Center

Hospital Affiliations

Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Drug, Device
Study Phase: Phase 4
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Enrollment Status: Completed
Publish Date: July 08, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

66 Total Publications

Neoadjuvant Treatment Strategies in Gastrointestinal Stromal Tumors.
Neoadjuvant Treatment Strategies in Gastrointestinal Stromal Tumors.
Journal: Hematology/oncology clinics of North America
Published: November 12, 2025
Similar Doctors
Melissa Hogg
Expertise in
50
conditions
Dr. Melissa Hogg
Surgical Oncology | General Surgery
Expertise in
50
conditions
Dr. Melissa Hogg
Surgical Oncology | General Surgery

Endeavor Health Medical Group

2650 Ridge Ave., Kellogg Cancer Center, 
Evanston, IL 
 (12.3 miles away)
847-570-1700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melissa Hogg, MD, a surgical oncologist at Endeavor Health, provides advanced, minimally invasive surgical care for patients with cancer and complex conditions. She specializes in robotic-assisted procedures and evidence-based treatment strategies that promote both longevity and quality of life. Dr. Hogg is also dedicated to surgical education and innovation, ensuring that advances in technology and training continue to enhance patient safety and outcomes. Dr. Hogg is highly rated in 50 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Gastrointestinal Fistula, Pancreaticoduodenectomy, and Pancreatectomy.

Shishir K. Maithel
Expertise in
29
conditions
Dr. Shishir K. Maithel
Surgical Oncology
Expertise in
29
conditions
Dr. Shishir K. Maithel
Surgical Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shishir Maithel is a Surgical Oncologist in Chicago, Illinois. Dr. Maithel has been practicing medicine for over 26 years is highly rated in 29 conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Cancer, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Hepatectomy.

Expertise in
16
conditions
Dr. Marco G. Patti
General Surgery | Surgical Oncology | Thoracic Surgery
Expertise in
16
conditions
Dr. Marco G. Patti
General Surgery | Surgical Oncology | Thoracic Surgery
5841 S Maryland Ave, Mc 5031, 
Chicago, IL 
 (7.4 miles away)
773-702-4865
Languages Spoken:
English

Marco Patti is a General Surgeon and a Surgical Oncologist in Chicago, Illinois. Dr. Patti is highly rated in 16 conditions, according to our data. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Achalasia, Hiatal Hernia, Endoscopy, and Gastric Bypass.

Frequently Asked Questions about Dr. Jeffrey D. Wayne

How do I make an appointment with Dr. Jeffrey D. Wayne?

You can book an appointment with Dr. Jeffrey D. Wayne by calling their office at 866-587-4322. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey D. Wayne a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey D. Wayne is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey D. Wayne specialize in?

While Dr. Jeffrey D. Wayne is a Surgical Oncology, they have specific expertise in Melanoma, Gastrointestinal Stromal Tumor, and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Jeffrey D. Wayne participate in research or clinical trials?

Yes. Dr. Jeffrey D. Wayne has published 66 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Jeffrey D. Wayne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey D. Wayne accept my insurance?

Dr. Jeffrey D. Wayne accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 866-587-4322 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wayne's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 9 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile